SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are ...
Lupus Foundation of America1mon
Investigational Therapy SC291 Receives FDA Fast Track Designation for Relapsed/Refractory Systemic Lupus Erythematosus
The U.S Food and Drug Administration (FDA) granted Fast Track Designation to Sana Biotechnology’s SC291 for relapsed/refractory systemic lupus erythematosus (SLE) treatment. SC291 is a hypoimmune (HIP ...
Seeking Alpha1mon
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
This is the release of initial data from its phase 1 study using SC291 for the treatment of patients with Systemic Lupus Erythematosus (SLE), extrarenal SLE, and lupus nephritis (LN). This will be ...
Business Insider1mon
Sana Biotechnology announces Fast Track designation for SC291
Sana Biotechnology (SANA) announced that the U.S. Food and Drug Administration granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes ...
MarketWatch1mon
Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy
Sana Biotechnology has been granted fast track designation to accelerate development of its proposed treatment for relapsed and refractory systemic lupus erythematosus. The U.S. Food and Drug ...
Business Insider1mon
ATTENTION SANA SHAREHOLDERS: Investors who lost money on Sana Biotechnology, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...
KTLA1mon
Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud Violations
Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...
Nasdaq1mon
Sana Biotechnology Receives FDA Fast Track Designation for SC291 in Treatment of Relapsed/Refractory Systemic Lupus Erythematosus
Sana Biotechnology's SC291 receives FDA Fast Track designation for treating relapsed/refractory systemic lupus erythematosus, with initial data expected in 2025. Sana Biotechnology, Inc. announced ...
Morningstar1mon
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025 SEATTLE, Dec. 02 ...
WGN Radio1mon
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025 SEATTLE, Dec. 02, 2024 ...
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including ...